加速度计衍生的运动特征作为神经重症监护中肌肉萎缩的预测生物标志物:一项前瞻性队列研究
这项单中心前瞻性观察性队列研究(MINCE注册研究的一部分)纳入53例神经重症监护患者,共91个加速度计数据集,评估入ICU后第3、7、10天股直肌相对于基线(第0天)的萎缩情况。结果显示第10天股直肌厚度变化为-19.5%(SD 12.0)。在12个变量中,基线股直肌肌肉量和主动运动比例(% activity)被选为肌肉萎缩的显著预测因子。将运动特征纳入预测模型后,在未见测试集上的性能显著提升(R²=79% vs 55%)。作者认为,反映活动水平的可量化生物标志物有助于更精确地表型化ICUAW,并可能指导个体化干预。
要点
- 神经重症监护患者入ICU第10天股直肌厚度较基线下降19.5%(SD 12.0)。
- 基线股直肌肌肉量(beta -5.1, 95% CI -7.9 to -3.8)和主动运动比例(beta 1.6, 95% CI 0.1 to 4.9)是肌肉萎缩的显著预测因子。
- 预测模型纳入运动特征后,在未见测试集上R²从55%提升至79%。
- 作者认为,加速度计测量的主动运动是神经重症监护患者肌肉萎缩的关键风险因素。
- 作者指出,需进一步研究以验证这些发现超越神经重症监护病房的外部有效性。
适用人群与场景
- 神经重症监护患者,纳入MINCE注册研究(代谢与营养在神经重症监护,DRKS-ID: DRKS00031472)。
- 筛查407例患者,最终纳入53例(年龄59.2岁,SD 15.9;男性31例,58.5%),共91个加速度计数据集。
研究设计与关键结果
- 研究类型:单中心、前瞻性、观察性队列研究,作为MINCE注册研究的一部分。
- 样本量与人群:筛查407例,纳入53例神经重症监护患者,共91个加速度计数据集;年龄59.2岁(SD 15.9),男性31例(58.5%)。
- 干预与对照:使用非侵入性、身体固定式加速度计计算主动运动指标,并开发机器学习模型预测肌肉萎缩;无对照组。
- 主要终点:入ICU后第3、7、10天评估股直肌相对于基线(第0天)的萎缩,作为广义线性混合模型的因变量,采用LASSO正则化和嵌套交叉验证。
- 关键结果:第10天股直肌厚度变化为-19.5%(SD 12.0)。
- 预测因子:在12个人口学、临床、营养和加速度计衍生变量中,基线股直肌肌肉量(beta -5.1, 95% CI -7.9 to -3.8)和主动运动比例(% activity)(beta 1.6, 95% CI 0.1 to 4.9)被选为肌肉萎缩的显著预测因子。
- 模型性能:纳入运动特征后,在未见测试数据集上R²=79%;不纳入运动特征时R²=55%。
证据类型、等级与局限
- 证据类型:单中心、前瞻性、观察性队列研究。
- 局限:作者指出,需进一步研究以验证这些发现超越神经重症监护病房的外部有效性。
对床旁实践的改变
- 作者认为,主动运动(通过大腿固定式加速度计测量)是神经重症监护患者肌肉萎缩的关键风险因素。
- 作者认为,反映活动水平的可量化生物标志物可支持更精确的ICUAW表型分析,并可能指导个体化干预以支持ICU中的活动。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Physical inactivity and subsequent muscle atrophy are highly prevalent in neurocritical care and are recognized as key mechanisms underlying intensive care unit acquired weakness (ICUAW). The lack of quantifiable biomarkers for inactivity complicates the assessment of its relative importance compared to other conditions under the syndromic diagnosis of ICUAW. We hypothesize that active movement, as opposed to passive movement without active patient participation, can serve as a valid proxy for activity and may help predict muscle atrophy. To test this hypothesis, we utilized non-invasive, body-fixed accelerometers to compute measures of active movement and subsequently developed a machine learning model to predict muscle atrophy.
METHODS: This study was conducted as a single-center, prospective, observational cohort study as part of the MINCE registry (metabolism and nutrition in neurointensive care, DRKS-ID: DRKS00031472). Atrophy of rectus femoris muscle (RFM) relative to baseline (day 0) was evaluated at days 3, 7 and 10 after intensive care unit (ICU) admission and served as the dependent variable in a generalized linear mixed model with Least Absolute Shrinkage and Selection Operator regularization and nested-cross validation.
RESULTS: Out of 407 patients screened, 53 patients (age: 59.2 years (SD 15.9), 31 (58.5%) male) with a total of 91 available accelerometer datasets were enrolled. RFM thickness changed - 19.5% (SD 12.0) by day 10. Out of 12 demographic, clinical, nutritional and accelerometer-derived variables, baseline RFM muscle mass (beta - 5.1, 95% CI - 7.9 to - 3.8) and proportion of active movement (% activity) (beta 1.6, 95% CI 0.1 to 4.9) were selected as significant predictors of muscle atrophy. Including movement features into the prediction model substantially improved performance on an unseen test data set (including movement features: R2 = 79%; excluding movement features: R2 = 55%).
CONCLUSION: Active movement, as measured with thigh-fixed accelerometers, is a key risk factor for muscle atrophy in neurocritical care patients. Quantifiable biomarkers reflecting the level of activity can support more precise phenotyping of ICUAW and may direct tailored interventions to support activity in the ICU. Studies addressing the external validity of these findings beyond the neurointensive care unit are warranted.
TRIAL REGISTRATION: DRKS00031472, retrospectively registered on 13.03.2023.
参考来源
- Schmidbauer ML, Putz T, Gehri L, et al. Accelerometer-derived movement features as predictive biomarkers for muscle atrophy in neurocritical care: a prospective cohort study. Crit Care. 2024. PMID: 39217360. doi:10.1186/s13054-024-05067-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。